Bostel Headed to San Francisco in January for Key Industry Meetings

January 21, 2020 · Boston

Bostel Technologies, LLC today announced that it will be at two key conferences in January in San Francisco. Bostel and its representatives will be in San Francisco starting Sunday, January 12, for the 7th Annual Dermatology Summit at the Palace Hotel. Following this meeting the Company will be present for the JP Morgan Healthcare Conference and the associated meetings that week. Parties who are interested in meeting the company can use the information at the bottom of this press release.

Melanoma and nonmelanoma skin cancer are now among the most common types of cancer, worldwide. Non-melanoma skin cancer is the 5th most commonly occurring cancer in men and women with over 1 million diagnoses worldwide in 2018, although this is likely to be an underestimate. Melanoma of the skin is the 19th most commonly occurring cancer in men and women, there were nearly 300,000 new cases in 2018.

More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. According to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. If detected early, the five-year mean survivability rate for melanoma is 99%. If undetected, or if detected to late, the consequences can be severe. Every hour, two people in the U.S. die from skin cancer.

About Bostel Technologies

Bostel Technologies LLC is a privately-held, Boston-headquartered medical technology company that has created a patented diagnostic platform called Melody™ that uses Dual Deep Learning technology to improve the clinical diagnoses of melanoma by applying an additional sonification (data to sound waves conversion) layer on deep learning algorithms.

For more information please visit https://www.BostelTechnologies.com.

Contact: Harry Keegan, CEO: hkeegan@bosteltechnologies.com

Prospective Clinical Study Using Melody Validates Its Utility as Diagnostic for Melanoma

May 30, 2019 · Boston

Bostel Technologies, LLC today announced that the globally respect medical journal The Lancet published results of a prospective clinical study that showed that Melody™, Bostel’s Dual Deep Learning Technology™, significantly improves the diagnostics accuracy of melanoma.

“We have leveraged sonification and artificial intelligence to create a new diagnostic paradigm with clinically-proven sensitivity and specificity,” commented Harry Keegan, Bostel’s Chief Executive Officer. “This patent protected platform empowers healthcare professionals to efficiently and effectively diagnose melanoma lesions using dermoscopy so they can focus on improving outcomes and helping their patients”.

Experimental studies have indicated a potential diagnostic role for deep learning algorithms in identifying skin cancer at varying sensitivities. Previously, it was demonstrated that diagnostics by dermoscopy are improved by applying an additional sonification (data to sound waves conversion) layer on deep. learning algorithms. The aim of the study was to determine the impact of image quality on accuracy of diagnosis by sonification employing a rudimentary skin magnifier with polarized light.

The publication (The Lancet, EBioMEdicine; May 2019, Volume 43, Pages 107–113) recounted that processing of dermoscopic images followed by sonification resulted in an accurate diagnostic output using skin magnifier with polarized light. This implyied that the quality of the dermoscope is not the major factor influencing DL diagnosis of skin cancer. Thus Melody, Bostels Dual Deep Learning technology platform might have great utility in assisting healthcare providers to better detect melanoma.

Melanoma and nonmelanoma skin cancer are now among the most common types of cancer, worldwide. Non-melanoma skin cancer is the 5th most commonly occurring cancer in men and women, with over 1 million diagnoses worldwide in 2018, although this is likely to be an underestimate. Melanoma of the skin is the 19th most commonly occurring cancer in men and women, there were nearly 300,000 new cases in 2018.

More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. According to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. If detected early, the five-year mean survivability rate for melanoma is 99%. If undetected, or if detected to late, the consequences can be severe. Every hour, two people in the U.S. die from skin cancer.

About Bostel Technologies

Bostel Technologies LLC is a privately-held, Boston-headquartered medical technology company that has created a patented diagnostic platform called Melody™ that uses Dual Deep Learning technology to improve the clinical diagnoses of melanoma by applying an additional sonification (data to sound waves conversion) layer on deep learning algorithms.

For more information please visit https://www.BostelTechnologies.com.

Contact: Harry Keegan, CEO: hkeegan@bosteltechnologies.com

May is Skin Cancer Awareness Month – Bostel Urges You to Act

May 01, 2019 · Boston

Bostel Technologies, LLC today recognized the May is Skin Cancer Awareness month and urged people to act now to make changes to minimize the risk of this growing issue.

“At Bostel we are focused on developing Melody, a new technology platform that healthcare providers can use to better detect melanoma,” commented Harry Keegan, Bostel’s Chief Executive Officer. “While we are encouraged by the clinical results we have seen and this gives us hope, making the right behavioral choices today can help ensure that people minimize their risk”.

According to the Skin Cancer Foundation, over 5 million cases of skin cancer are diagnosed each year, making it the most common cancer in the United States. Fortunately, skin cancer is also one of the most preventable forms of cancer. About 90 percent of nonmelanoma skin cancers and 85 percent of melanoma cases are associated with exposure to ultraviolet radiation from the sun. By raising awareness of the dangers of unprotected exposure and encouraging sun-safe habits, we can change behaviors and save lives.

More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. According to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. If detected early, the five-year mean survivability rate for melanoma is 99%. If undetected, or if detected to late, the consequences can be severe. Every hour, two people in the U.S. die from skin cancer.

We encourage people to log on the the Skin Cancer Foundation website to learn what you can do to get involved: https://www.skincancer.org/get-involved/skin-cancer-awareness-month/

About Bostel Technologies

Bostel Technologies LLC is a privately-held, Boston-headquartered medical technology company that has created a patented diagnostic platform called Melody™ that uses Dual Deep Learning technology to improve the clinical diagnoses of melanoma by applying an additional sonification (data to sound waves conversion) layer on deep learning algorithms.

For more information please visit https://www.BostelTechnologies.com.

Contact: Harry Keegan, CEO: hkeegan@bosteltechnologies.com

Bostel Dual Deep Learning Technology Significantly Improves Diagnostic Accuracy of Melanoma

February 15, 2019 · Boston

Bostel Technologies, LLC today announced that the globally respect medical journal The Lancet published results of a retrospective study that showed that Melody™, Bostel’s Dual Deep Learning Technology™, significantly improves the diagnostics accuracy of melanoma.

“We have leveraged sonification and artificial intelligence to create a new diagnostic paradigm with clinically-proven sensitivity and specificity,” commented Harry Keegan, Bostel’s Chief Executive Officer. “This patent protected platform empowers healthcare professionals to efficiently and effectively diagnose melanoma lesions using dermoscopy so they can focus on improving outcomes and helping their patients”.

The publication (The Lancet, EBioMEdicine; February 2019, volume 40, pages 176–183) details the results from two parallel studies that were conducted: a laboratory retrospective study (LABS, n = 482 biopsies) and a non-interventional prospective observational study (OBS, n = 63 biopsies). Using Melody’s Dual Deep Learning Technology, which leverages dermoscopy and adds a second stage of processing that includes a deep learning algorithm of sonification and heuristic inspection with machine learning, significantly improves diagnostic accuracy.

Melanoma and nonmelanoma skin cancer are now among the most common types of cancer, worldwide. Non-melanoma skin cancer is the 5th most commonly occurring cancer in men and women,with over 1 million diagnoses worldwide in 2018, although this is likely to be an underestimate. Melanoma of the skin is the 19th most commonly occurring cancer in men and women, there were nearly 300,000 new cases in 2018.

More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. According to the Skin Cancer Foundation, one in five Americans will develop skin cancer by the age of 70. If detected early, the five-year mean survivability rate for melanoma is 99%. If undetected, or if detected to late, the consequences can be severe. Every hour, two people in the U.S. die from skin cancer.

About Bostel Technologies

Bostel Technologies LLC is a privately-held, Boston-headquartered medical technology company that has created a patented diagnostic platform called Melody™ that uses Dual Deep Learning technology to improve the clinical diagnoses of melanoma by applying an additional sonification (data to sound waves conversion) layer on deep learning algorithms.

For more information please visit https://www.BostelTechnologies.com.

Contact: Harry Keegan, CEO: hkeegan@bosteltechnologies.com